Overview
AMGN market data
Price History
AMGN price chart
Valuation & Profitability
- P/E (TTM)
- 25.84 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $14.23 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.4% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 23.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $269.77 – $421.79 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $225.9B · P/B 20.36 · P/S 5.93.
Company News
Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $380Benzinga · Aug 14, 2026, 2:17 PM
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'Benzinga · Aug 13, 2026, 2:41 AM
Reported Earlier, Amgen To Open New Science And Innovation Center At Genome Valley In HyderabadBenzinga · Aug 12, 2026, 10:21 AM
Guggenheim Maintains Neutral on Amgen, Raises Price Target to $388Benzinga · Aug 10, 2026, 1:43 PM
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's ZepboundThe Motley Fool · Aug 7, 2026, 8:15 PM
Citigroup Maintains Neutral on Amgen, Raises Price Target to $405Benzinga · Aug 7, 2026, 8:07 PM
Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’Benzinga · Aug 7, 2026, 12:05 PM
CNBC Halftime Report Final Trades: Amgen, Toast, ChubbBenzinga · Aug 6, 2026, 5:01 PM
Bernstein Maintains Market Perform on Amgen, Raises Price Target to $345Benzinga · Aug 6, 2026, 4:33 PM
UBS Maintains Buy on Amgen, Raises Price Target to $440Benzinga · Aug 5, 2026, 8:54 PM